We are live on ! Find out more
74.44 USD
-0.12
0.16%
At close Updated Nov 18, 4:00 PM EST
Pre-market
After hours
75.92
+1.48
1.99%
1 day
-0.16%
5 days
-5.22%
1 month
10.97%
3 months
61.2%
6 months
261.53%
Year to date
288.92%
1 year
372.34%
5 years
68.68%
10 years
2,263.17%
 

About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Employees: 765

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 44%
Neutral 48%
Negative 8%
Positive
Zacks Investment Research
1 day ago
Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 28.1% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet
Neutral
Investors Business Daily
9 days ago
ARK Invest Dumps These Shares While They're Hot, Buys Chips The Size Of Your Face
Cathie Wood's ARK Invest bought and sold medtech shares Friday. She also bought shares of an unconventional AI chipmaker — an unpopular one at that.
ARK Invest Dumps These Shares While They're Hot, Buys Chips The Size Of Your Face
Neutral
Business Wire
12 days ago
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of common stock. The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniver.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Zacks Investment Research
12 days ago
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
Neutral
Seeking Alpha
14 days ago
Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
The top contributors to the Portfolio's relative performance in the quarter were Kodiak Sciences, Flotek Industries, and Hyperliquid Strategies. The most significant detractors from the Portfolio's relative performance in the quarter were Vishay Precision Group, Babcock & Wilcox, and CareDx (not held). The salient changes to positioning this quarter included our increased exposure to Health Care and decreased exposure to Industrials.
Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
Neutral
Seeking Alpha
15 days ago
Baron Discovery Fund Q3 2026 Portfolio Activity
During the quarter, we initiated a position in Jersey Mike's Subs Inc., a franchisor of fast casual, submarine-style sandwich restaurants. We participated in the IPO of Lyntris Inc., a fast-growing proprietary defense solutions provider with a 90% sole-sourced portfolio exposed to many of the nation's key defense offerings. We sold our position in Wingstop Inc. during the quarter to allocate the proceeds into other restaurant companies where we felt there was better upside potential.
Baron Discovery Fund Q3 2026 Portfolio Activity
Positive
Zacks Investment Research
15 days ago
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CDNA raises its 2026 revenue and profit outlook as transplant testing demand and NavDx growth accelerate, with new molecular diagnostics set for 2027 launches.
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
Neutral
Business Wire
15 days ago
CareDx Announces Third KOAR Analysis Published in Transplantation
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multicenter study, in the journal Transplantation. The third manuscript from KOAR investigated the correlation between early post-transplant AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) levels and thr.
CareDx Announces Third KOAR Analysis Published in Transplantation
Positive
The Motley Fool
19 days ago
Why CareDx Stock Soared Today
CareDx is a leader in the fast-growing field of medical diagnostics. The company is working to bring its non-invasive tests to new markets.
Why CareDx Stock Soared Today
Neutral
Seeking Alpha
19 days ago
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™